Panel Discussion: An Overview of the Hippo Pathway Drug Development Landscape
Time: 9:00 am
day: Conference Day One
Details:
- What indications are showing most promise for therapeutic intervention on the Hippo pathway?
- Will targeted approaches on TEAD isoforms be the key to navigating risk of toxicity from pan-TEADs?
- How do we convince investors Hippo pathway treatments are worth their time when some consider the pathway ‘unvalidated’?
- What are the advantages/risks in targeting YAP/TAZ and TEAD interactions?
